Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 11Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1Advanced Cancers 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × ridaforolimus × Clear all
NCT00836927 2019-02-18

MK-8669-038

Merck Sharp & Dohme LLC

Phase 2 Terminated
7 enrolled 13 charts

Advanced Cancers

NCT00818675 2015-01-21

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Merck Sharp & Dohme LLC

Phase 2 Terminated
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡